Houston-based Decisio's virtual care technology has been paired with GE Healthcare and Microsoft technology in a new initiative for hospitals dealing with the COVID-19 outbreak. Photo via decisiohealth.com

Houston-based health tech startup Decisio Health Inc. has been enlisted in the war against the novel coronavirus.

Chicago-based GE Healthcare Inc. has tapped Decisio's AI-powered DECISIOInsight software, which enables health care providers to remotely monitor patients, for an initiative involving Redmond, Washington-based Microsoft Corp. that's designed to help treat COVID-19 patients.

The coronavirus-targeted Mural Virtual Care Solution, which was introduced April 15, marries Decisio's virtual monitoring software with GE Healthcare's telehealth technology and Microsoft's Azure cloud-computing platform. It's designed to offer hospitals a broad view of COVID-19 patients who are hooked up to ventilators in ICUs. This platform merges data from ventilators, patient monitoring systems, electronic health records, labs, and other sources.

This special technology package is a stripped-down version of the Mural Virtual Care Solution, which pairs Decisio's and GE Healthcare's technology to virtually track hospital patients. GE Healthcare invested in Decisio in 2019.

Until January 31, 2021, the Mural coronavirus bundle is being provided at no cost to hospitals. Among the users is Oregon Health & Science University in Portland.

"We're trying to carry as much of the cost burden to make this as sustainable as possible for our hospital partners that we know are hurting economically right now," says Bryan Haardt, CEO of Decisio.

"There has to be a moralistic compass," he adds. "You have to be driven by something more than just profit."

GE Healthcare, which contributed to Decisio's $13 million Series B round in December, was already partnering with the startup on the Mural Virtual Care Solution. Microsoft was brought into the mix to speed up delivery of the platform in response to the coronavirus pandemic.

"This relationship did not exist prior to this initiative," Haardt says. "We all came together and said, 'Guys, we've got to do our part. It is absolutely a moral imperative that we get together.' And we said, 'OK, well, what are the parts?'"

Haardt says this project equips hospitals to adhere to the best standards of care when it comes to treating COVID-19 patients who are relying on ventilators. In a COVID-19 treatment setting, one of the key benefits of the Mural Virtual Care Solution is that a health care clinician can monitor a patient's vital signs and other data without physical contact, he says.

Founded in 2013, Decisio built its virtual health platform using technology licensed from and developed at the University of Texas Health Science Center in Houston. Coupling real-time clinical surveillance with data visualization, the DECISIOInsight software can pinpoint risks and guide clinicians toward better decisions about patient care.

Haardt says Decisio's software aims to reduce the rate of hospital deaths, length of hospital stays, and burden on hospital resources by helping health care providers decrease the severity of hospital-acquired infections, pneumonia, the flu, and other conditions. Baylor St. Luke's Medical Center in Houston is among the customers for Decisio and GE Healthcare's broad-based Mural Virtual Care Solution, which was rolled out last year.

Also, Decisio has teamed up with professional services firm Deloitte to deliver virtual patient monitoring at U.S. Department of Defense hospitals. This technology is being piloted at Brooke Army Medical Center in San Antonio and Naval Medical Center San Diego.

"We look at doctors and nurses as heroes, because they're really good at getting people out of trouble," Haardt says. "And we like to think of our solution as keeping people out of trouble, because if you can keep them out of the trouble, then these heroic, herculean efforts [by doctors and nurses] are not required as much … ."

Haardt explains that Decisio's technology can monitor patient activity and detect patient trends in not just one area of a hospital (such as an ICU) or throughout an entire hospital but across a commonly managed group of hospitals. Those insights help hospitals ensure all of their health care professionals are following the same treatment protocols.

The No. 1 economic detriment to hospitals "is doing things different at all their different facilities," Haardt says. "If you can reduce the variability of care, we know the cost to provide goods and services goes down, and we know the outcomes improve."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.